Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study. (PubMed, Clin Gastroenterol Hepatol) - Sep 30, 2026 - "In this large real-world UC cohort, upadacitinib was associated with the lowest risk of treatment failure and greatest corticosteroid-free disease stability compared with all other ATs evaluated."
Journal • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
|
|
Anna Silverman; Ashwin N Ananthakrishnan; Dhruv Ahuja; Kuan-Hung Yeh; Marianne Hupé; Ola Olén; Ronghui Xu; Sagar B Patel; Shane W Goodwin; Siddharth Singh; Sudheer Kumar Vuyyuru; Vipul Jairath
|